Krebs Biochemicals & Industries Ltd Financials
Company Logo

Krebs Biochemicals & Industries Ltd Financial Statement

Krebs Biochemicals & Industries Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue12.92
Operating Expense15.09
Net Profit-5.17
Net Profit Margin-40.02
Earning Per Share-2.40
EBIDTA-2.16
Effective Tax RateTBA

Krebs Biochemicals & Industries Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual50.42
Operating Expenses Annual59.15
Operating Profit Annual-8.27
Interest Annual4.69
Depreciation6.77
Net Profit Annual-19.73
Tax AnnualTBA

Krebs Biochemicals & Industries Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.09
Cash Flow from Operations2.30
Cash Flow from Investing-7.82
Cash Flow from Financing5.56
Cash Flow at the End0.14

Krebs Biochemicals & Industries Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-16.40
PBIT Margin (%)-29.83
PBT Margin (%)-23.46
Net PROFIT Margin (%)-39.13
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-14.87
Total Debt / Equity (X)2.83
Asset Turnover Ratio (%)0.38

Krebs Biochemicals & Industries Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual151.80
Total Current Assets Annual17.44
Non Current Assets Annual160.73
Total Shareholders Funds Annual-119.22
Total Assets Annual178.17

Krebs Biochemicals & Industries Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Oct 16, 2024, Krebs Biochemicals & Industries Ltd has a market capitalization of 131.56 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Krebs Biochemicals & Industries Ltd is debt-free with a debt-to-equity ratio of -1.62.
In FY 2023 , Krebs Biochemicals & Industries Ltd recorded a total revenue of approximately 50.42 Cr marking a significant milestone in the company's financial performance.
Krebs Biochemicals & Industries Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.4% and -0.1% annually, respectively..
Krebs Biochemicals & Industries Ltd's current PE ratio is -6.67.
Krebs Biochemicals & Industries Ltd's ROCE averaged -20.1% from the FY ending March 2022 to 2024, with a median of -16.0%. It peaked at -12.0% in March 2024, reflecting strong capital efficiency over the period..
Krebs Biochemicals & Industries Ltd's latest EBIT is Rs. -15.04 Cr, surpassing the average EBIT of Rs. -25.30 Cr over the 5 years..